newsfilter
← Latest News
GlobeNewswire·

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction (PH-HFpEF)Expansion of U.S.